Jubilant Ingrevia Ltd Q1 FY26 Earnings Analysis
Published 6 Jul 2026 | Chemicals & Petrochemicals | Market Cap: ₹11.9K Cr
Price
₹735
Market Cap
₹11.9K Cr
P/E Ratio
37.4
How does Jubilant Ingrevia Ltd rank in Chemicals & Petrochemicals?
Compare Jubilant Ingrevia Ltd against every Chemicals & Petrochemicals company this quarter on revenue, margins and earnings-call signals.
Jubilant Ingrevia Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.2K Cr, net profit ₹86 Cr.
Full financials →Earnings Summary
Specialty Chemicals and Nutrition segments expected to sustain strong growth; these now contribute ~63% of revenue and 90% of EBITDA. Specialty and Nutrition segments contribute ~63% of revenue and ~90% of EBITDA, expected to sustain strong growth and margin expansion.
📊 Revenue & Sales Performance
- →Specialty Chemicals and Nutrition segments expected to sustain strong growth; these now contribute ~63% of revenue and 90% of EBITDA.
- →Anticipated 20%-25% year-on-year growth driven by specialty chemicals and export growth, offsetting feed segment volatility.
- →Pharma CDMO business funnel doubled in last year; strong traction with innovators and tier-1 CDMOs in US, EU, Japan.
- →CDMO agro plant capacity expansion underway; first agro contract deliveries started; big CDMO order supply expected early 2026.
- →Semiconductor segment has 12+ molecules in pipeline; focus on high-value, low-volume products with expected commercial-stage progress.
- →New multi-purpose plants under construction and debottlenecking ongoing to enhance capacity by 15-20%.
- →Nutrition segment sees growth potential in food and cosmetic segments; new Niacinamide plant commissioned with expected volume ramp-up.
- →Overall, expect revenue and margin growth through FY ’26-27, with Rs. 2000 crore CAPEX utilization targeted at 70%-80% by FY’27.
📈 Profitability & Margins
- →Specialty and Nutrition segments contribute ~63% of revenue and ~90% of EBITDA, expected to sustain strong growth and margin expansion.
- →FY’26 targeted annualized cost savings of Rs 100+ crore through Lean 2.0 program to improve margins.
- →CDMO business capacity utilization expected to reach 70%-80% by FY’27, supporting topline growth.
- →Big Agro CDMO order supplies to start early 2026, accelerating growth trajectory.
- →Specialty Chemicals segment EBITDA grew 52% YoY in Q1 FY’26, with margins at 27%, indicating margin expansion potential.
- →Acetyls segment expected to recover gradually, improving overall profitability.
- →Pipeline of 70 molecules with multi-geography opportunities in pharma, agro, and other sectors, supporting future revenue growth.
- →Revenue growth guidance of 20%-25% year-on-year for Specialty and exports segments driven by new capacities and market expansion.
- →PAT rose 54% YoY in Q1 FY’26, indicating strong near-term profit growth momentum.
🏗️ Capital Expenditure Plans
- →Rs. 2000 crore invested recently, with 70% allocated to specialty chemicals, mainly for multipurpose and dedicated plants serving CDMO and Fine Chemicals businesses.
- →Major ongoing CAPEX includes a big dedicated plant for an agro CDMO contract at Bharuch, expected to complete by end FY’26.
- →Additional CAPEX projects: new boiler at Bharuch (commissioning expected Q2 FY’26), debottlenecking existing plants at Bharuch and Gajraula to increase capacity by 15-20%, and a new multi-purpose plant (MPP8) at Gajraula with construction starting soon.
- →Niacinamide plant commissioned in March is being converted to a multi-purpose plant for human nutrition.
- →FY’26 planned CAPEX of Rs. 600 crore focused on supporting growth, including the $300 million big agro CDMO contract, with deliveries to start early 2026.
- →Continued investments in R&D and capacity expansions to support CDMO pipeline and specialty segments.
💰 Fundraising & Capital Structure
- →There is no mention of any current or upcoming fundraising through debt or equity in the transcript.
- →The company’s net debt as of June 30, 2025, stands at Rs. 700 crore with a stable net debt to EBITDA ratio of 1.18x.
- →Capital expenditure for the quarter was primarily funded through internal accruals.
- →For FY’26, the company plans to invest Rs. 600 crore in CAPEX, expected to be funded internally.
- →No disclosures or indications regarding new debt or equity issuance were made during the call.
📋 Order Book & Pipeline
- →Jubilant Ingrevia has a robust CDMO order book with over 70 active molecules in the pipeline, representing a multi-thousand crore addressable market.
- →The pharma segment funnel has doubled in the last year, engaging with over 30 key global accounts across EU, US, and Japan.
- →In agro CDMO, the company has announced two contracts last year and expects 5-6 more contracts in advanced stages, with deliveries already started on the first agro CDMO order.
- →A significant $300 million agro CDMO contract is in execution, with plant commissioning and supplies expected early 2026.
- →Several other discussions with innovators in agro and semiconductor segments are ongoing, with 12+ opportunities in semiconductor.
- →Overall, order confirmations are expected in the coming months to quarters, reflecting a growing and diversified pending orderbook supporting future growth.
Key Metrics
Frequently Asked Questions
What were Jubilant Ingrevia Ltd Q1 FY26 results?
Specialty Chemicals and Nutrition segments expected to sustain strong growth; these now contribute ~63% of revenue and 90% of EBITDA. Specialty and Nutrition segments contribute ~63% of revenue and ~90% of EBITDA, expected to sustain strong growth and margin expansion.
What is Jubilant Ingrevia Ltd share price analysis?
Jubilant Ingrevia Ltd currently shows a neutral. The stock trades at a P/E of 37.4 with a market cap of ₹11,884 Cr. Investors should review the full earnings analysis for detailed insights.
Is Jubilant Ingrevia Ltd planning capital expenditure?
Rs.
Keep Jubilant Ingrevia Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.